Item 5.07 Submission of Matters to a Vote of Security Holders.

Health Sciences Acquisitions Corporation 2 (the "Company") held an extraordinary general meeting of Shareholders (the "General Meeting") at 10:30 a.m. Eastern Time on July 26, 2022 for the purposes of considering and voting upon:

? a special resolution (the "Extension Proposal") to amend the Company's amended

and restated memorandum and articles of association to: (a) extend from August

6, 2022 (the "Original Termination Date') to November 6, 2022 (the "Extended

Date"), the date by which, if the Company has not consummated a merger,

amalgamation, share exchange, asset acquisition, share purchase, reorganisation

or similar business combination involving one or more businesses or entities,

the Company must: (i) cease all operations except for the purpose of winding

up; (ii) as promptly as reasonably possible but not more than ten business days

thereafter, redeem the shares sold in the Company's initial public offering;

and (iii) as promptly as reasonably possible following such redemption

liquidate and dissolve, subject in each case to its obligations under Cayman

Islands law to provide for claims of creditors and in all cases subject to the

other requirements of applicable law, and (b) allow the Company, without

another shareholder vote, to elect to extend the date to consummate a business

combination on a monthly basis for up to three times by an additional one month

each time after the Extended Date, upon five days' advance notice prior to the

applicable deadlines, until February 6, 2023 or a total of up to six months

after the Original Termination Date, unless the closing of the Company's

initial business combination shall have occurred.

? a proposal (the "Adjournment Proposal") by ordinary resolution to approve the

adjournment of the General Meeting by the chairman thereof to a later date, if

necessary, under certain circumstances, to solicit additional proxies for the

purpose of approving the Extension Proposal, to amend the Extension Proposal,

or to allow reasonable additional time for the filing or mailing of any

supplemental or amended disclosure that the Company has determined in good

faith after consultation with outside legal counsel is required under

applicable law and for such supplemental or amended disclosure to be

disseminated and reviewed by the Company's shareholders prior to the General

Meeting; provided that the General Meeting is reconvened as promptly as

practical thereafter. The Adjournment Proposal would be presented at the

General Meeting if there were not sufficient votes to approve the Extension


   Proposal.

For more information on these proposals, please refer to the Company's proxy statement dated July 1, 2022, as supplemented on July 12, 2022 and July 18, 2022 (the "Proxy Statement"). As of the record date of June 27, 2022, there were a total of 20,450,000 ordinary shares issued and outstanding and entitled to vote at the General Meeting. Proxies were received for 16,450,058 ordinary shares, or approximately 80.4% of the shares issued and outstanding and entitled to vote at the General Meeting; therefore a quorum was present.

Shareholders voted to approve the Extension Proposal. The proposal received the following final voting results:





    For            Against        Abstain
  15,084,246       1,365,812           0

The Adjournment Proposal was not presented to the shareholders because (as disclosed in the Proxy Statement) there were sufficient votes to approve the Extension Proposal.





                                       1

© Edgar Online, source Glimpses